Amid overwhelming public demand for alternative COVID-19 vaccines, IHH Singapore officially began offering its first batch of 10,000 doses of the Sinopharm COVID-19 vaccine on 30 August.
With this first batch of 10,000 doses offered across Gleneagles Hospital, Mount Elizabeth Hospital and Parkway Shenton clinics in Duxton and One Raffles Quay, IHH Singapore is able to inoculate some 5,000 people.
Dr Noel Yeo, Chief Operating Officer of IHH Healthcare Singapore, said that more than 6,000 individuals had registered their interest to receive the Sinopharm vaccine even before it was made available.
"We were aware there is a demand for alternative vaccines. However, the response for Sinopharm has been overwhelming. We are making plans for second orders but we have to clear approvals from HSA (Health Sciences Authority) first,” he said.
For those looking for alternative vaccines, the Sinopharm vaccine has a reported higher efficacy rate compared to the Sinovac vaccine - 79 per cent compared to 51 per cent - and reportedly milder side effects.
Related Stories
.jpg?sfvrsn=21d67f46_1)
IHH Singapore Collaborates with Insurers to Improve Affordability of Private Hospital Care
Taking Preventive Health to New Heights at The IHH Sky Race | Merdeka 118
IHH Healthcare Malaysia highlights Care. For Good. through its role as title partner and official medical provider of The IHH Sky Race | Merdeka
Gleneagles Hospital Hong Kong Highlights Healthcare at ITB China 2026
Travel today is no longer defined by destinations alone — it is shaped by the confidence and assurance travellers carry with them.
IHH Malaysia Strengthens Care Integration Through GP-Specialist Collaboration
A referral is more than an appointment with another doctor, it is an act of trust.
Parkway MediCentre Xintiandi Launches Integrated Chinese and Western Medicine Health Management Services
Themed "Echoes of the World, Pulse of China", Parkway MediCentre Xintiandi showcased the role of Traditional Chinese Medicine (TCM) through an integrated healthcare approach.
Fortis Memorial Research Institute (FMRI) Launches India's First Centre of Excellence for Myeloma and Lymphoma
Officiated on 11 June, the FMRI Centre of Excellence, brings a highly specialised, patient‑centred and research‑driven approach to managing blood cancers.
